NextCure, Inc.

NXTCReported to SECin USCIK 0001661059Filings at SEC EDGAR

No score on this page, by design. Everything here is a fact from a public U.S. register: insider filings at the SEC (Form 4), lobbying filings under the Lobbying Disclosure Act, trades reported by members of Congress under the STOCK Act, and fund holdings in 13F filings. Our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.

This page is free to read, and it stops after 5 rows. Those are the 5 most recent Form 4 lines at this company, out of 14. Reading the whole list, and the full version of each filer's page, is part of the subscription. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

The most recent filings

Most recent filing first: every line of every Form 4 at this company that passed our review, the same lines as on the register. Reported is the day the filing reached the SEC, usually within two business days of the trade. Amounts are in U.S. dollars, as the form states them.

5 of 14
Form 4 lines at NextCure, Inc., most recent filing first
Filed byTypeValueReportedFiled byValueTypeSharesReported
Simcere Zaiming, Inc.—Open-market sell$184,80030,000 sharesAug 12, 2026Simcere Zaiming, Inc.$184,800Sell · Aug 12Open-market sell30,000Aug 12, 2026
ADAR1 Capital Management, LLC—Open-market buy$38,4148,003 sharesAug 3, 2026ADAR1 Capital Management, LLC$38,414Buy · Aug 3Open-market buy8,003Aug 3, 2026
ADAR1 Capital Management, LLC—Open-market buy$124,54025,000 sharesAug 3, 2026ADAR1 Capital Management, LLC$124,540Buy · Aug 3Open-market buy25,000Aug 3, 2026
ADAR1 Capital Management, LLC—Open-market buy$16,4203,300 sharesAug 3, 2026ADAR1 Capital Management, LLC$16,420Buy · Aug 3Open-market buy3,300Aug 3, 2026
ADAR1 Capital Management, LLC—Open-market buy$385,79377,850 sharesAug 3, 2026ADAR1 Capital Management, LLC$385,793Buy · Aug 3Open-market buy77,850Aug 3, 2026